Ceryvyn Therapeutics Ltd
OPT
Peringkat dalam Saham
#31857
Opthea Limited is an Australian clinical-stage biopharmaceutical company... Opthea Limited is an Australian clinical-stage biopharmaceutical company focused on developing and commercializing therapies primarily for eye diseases. The foundation of its development efforts lies in its intellectual property portfolio, which targets Vascular Endothelial Growth Factors (VEGF-C, VEGF-D, and VEGF Receptor-3). This technology is designed to address conditions linked to the growth of blood and lymphatic vessels, as well as vascular leakage. The company's leading asset, OPT 302, is a soluble form of VEGFR3 currently undergoing clinical trials. This novel therapy aims to treat wet neovascular age-related macular degeneration (wet AMD) and diabetic macular edema (DME). OPT 302 is distinguished as a first-in-class VEGF-C/D inhibitor, intended to be used in conjunction with VEGF-A inhibitors for the treatment of wet AMD and various other retinal diseases. Originally incorporated in 1984 as Circadian Technologies Limited, the company rebranded to Opthea Limited in December 2015 and is headquartered in South Yarra, Australia.
Harga Saham
$0.00846342
Terakhir disinkronkan: 2026-07-27
Kapitalisasi Pasar
$11.27M
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
-99.75%
Negara
AU
Perdagangan Ceryvyn Therapeutics Ltd (OPT)
Kategori
Healthcare
Jumlah saham beredar untuk Ceryvyn Therapeutics Ltd (OPT)
Jumlah saham beredar per June 2025: 153.78M
Menurut laporan keuangan terbaru dan harga saham Ceryvyn Therapeutics Ltd, jumlah saham beredar saat ini adalah 153.78M. Pada akhir June 2024, perusahaan memiliki 79.78M saham beredar. Jumlah saham beredar biasanya dipengaruhi oleh pemecahan saham dan pembelian kembali saham.
Riwayat saham beredar untuk Ceryvyn Therapeutics Ltd (OPT) dari 2000 hingga 2026
Saham beredar pada akhir setiap tahun
| Tahun | Saham Beredar | Mengubah |
|---|---|---|
| 2026 (TTM) | 153.78M | 0.45% |
| 2025 | 153.09M | 91.90% |
| 2024 | 79.78M | 35.92% |
| 2023 | 58.69M | 25.91% |
| 2022 | 46.62M | 9.71% |
| 2021 | 42.49M | 30.49% |
| 2020 | 32.56M | 11.90% |
| 2019 | 29.10M | 0.27% |
| 2018 | 29.02M | 25.03% |
| 2017 | 23.21M | 7.34% |
| 2016 | 21.62M | 49.48% |
| 2015 | 14.47M | 119.26% |
| 2014 | 6.60M | 8.67% |
| 2013 | 6.07M | -3.84% |
| 2012 | 6.31M | 0.63% |
| 2011 | 6.27M | 2.22% |
| 2010 | 6.14M | 1.38% |
| 2009 | 6.05M | 2.44% |
| 2008 | 5.91M | 0.00% |
| 2007 | 5.91M | 8.57% |
| 2006 | 5.44M | -7.89% |
| 2005 | 5.91M | -0.12% |
| 2004 | 5.92M | 5.63% |
| 2003 | 5.60M | 0.09% |
| 2002 | 5.60M | 7.02% |
| 2001 | 5.23M | 17.30% |
| 2000 | 4.46M | 0.00% |
Saham beredar untuk perusahaan serupa atau pesaing
| Perusahaan | Saham Beredar | Perbedaan | Negara |
|---|---|---|---|
| 253.90M | 65.11% |
US
|
|
| 396.00M | 157.51% |
US
|
|
| 478.91M | 211.43% |
AU
|
|
| - | - |
CH
|
|
| 62.19M | -59.56% |
NL
|
